J&J, Gen­mab strength­en case for Darza­lex in front­line mul­ti­ple myelo­ma with fresh slate of PhI­II da­ta

J&J and Gen­mab of­fered a snap­shot of the Phase III da­ta that got Darza­lex its pri­or­i­ty re­view for front­line use late last week, high­light­ing how …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.